Circulating tumor-specific DNA: a stony road to clinical utility

Biomark Med. 2020 Apr;14(5):331-333. doi: 10.2217/bmm-2019-0552. Epub 2020 Apr 6.

Authors

Caroline B Thomsen¹, Anders Jakobsen^{1

2}

Affiliations

¹ Danish Colorectal Cancer Center South, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
² Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

PMID: 32250154
DOI: 10.2217/bmm-2019-0552

No abstract available

Keywords: minimal residual disease; treatment monitoring; tumor DNA.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / blood*
Circulating Tumor DNA / blood*
Humans
Neoplasms / blood
Neoplasms / drug therapy

Substances

Antineoplastic Agents
Biomarkers, Tumor
Circulating Tumor DNA